Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Fibroblast growth factor signalling: from development to cancer
There is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumour types, and clinical reagents that specifically target the FGFs or FGF receptors are being developed. Expand
Hallmarks of 'BRCAness' in sporadic cancers
There are properties that define 'BRCAness' — that is, traits that some sporadic cancers share with those occurring in either BRCA1- or BRCa2-mutation carriers, which might have important implications for the clinical management of these cancers. Expand
The history and future of targeting cyclin-dependent kinases in cancer therapy
- U. Asghar, A. Witkiewicz, N. Turner, E. Knudsen
- Biology, Medicine
- Nature Reviews Drug Discovery
- 1 February 2015
How CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity is discussed. Expand
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
The results indicate that PARP inhibition might be a useful therapeutic strategy not only for the treatment of BRCA mutation-associated tumors but also for a wider range of tumors bearing a variety of deficiencies in the HR pathway or displaying properties of 'BRCAness. Expand
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy…
This study aimed to confirm the earlier findings with this extended follow-up and show the results for subgroup and biomarker analyses, and assesses endocrine therapy resistance by clinical parameters, quantitative hormone-receptor expression, and tumour PIK3CA mutational status in circulating DNA at baseline. Expand
BRCA1 dysfunction in sporadic basal-like breast cancer
The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer. Expand
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
The data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance. Expand
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
It is possible that further follow-up may reveal long-term toxic effects of palbociclib to fulvestrant that disturb the regular administration of the combination therapy or hamper the use of subsequent therapies. Expand
Treating cancer with selective CDK4/6 inhibitors
Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage oestrogen receptor (ER)-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile. Expand
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- G. Schiavon, S. Hrebien, +14 authors N. Turner
- Science Translational Medicine
- 11 November 2015
ESR1 mutations are rarely acquired during adjuvant AI but are commonly selected by therapy for metastatic disease, providing evidence that mechanisms of resistance to targeted therapy may be substantially different between the treatment of micrometastatic and overt metastatic cancer. Expand